Clinical Trials
24 trialsNCT06953453 2025-09-25
A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors
Lee's Pharmaceutical Limited
Phase 1 Recruiting
NCT00263575 2024-06-18
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT00683995 2020-08-28
A Phase III Clinical Study of KW-2246
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT00684632 2020-08-28
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT00293033 2019-11-18
Study of BEMAâ„¢ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
BioDelivery Sciences International
Phase 3 Completed
NCT00696137 2019-09-24
Long-term Extension Study of BEMAâ„¢ Fentanyl
BioDelivery Sciences International
Phase 3 Completed
NCT01315886 2017-04-05
Conversion From Fast Acting Oral Opioids to Abstral®
Orexo AB
Phase 4 Terminated
NCT01902524 2014-08-28
Efficacy and Safety Study of Fentanyl Transdermal Patch for Treatment of Chronic Pain
Janssen Korea, Ltd., Korea
Phase 4 Completed
NCT00236041 2014-05-09
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00236093 2014-05-09
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00458510 2013-07-11
Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain
Archimedes Development Ltd
Phase 3 Completed
NCT00644787 2013-06-13
A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain
Janssen Pharmaceutical K.K.
Phase 2/3 Completed
NCT00641667 2013-06-07
An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain
Janssen Pharmaceutical K.K.
Phase 3 Completed
NCT00236145 2013-01-29
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Completed
NCT00842829 2012-10-01
Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 4 Terminated
NCT00355628 2012-08-31
Clinical Study of KW-2246 in Patients With Cancer Pain
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT00279344 2012-05-07
Efficacy and Safety of FITpatch Compared to Standard Opioid Treatment in Cancer Pain (FT-015-IN)
Nycomed
Phase 3 Completed
NCT00345735 2012-05-07
Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)
Nycomed
Phase 2 Completed
NCT00362583 2012-05-07
Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)
Nycomed
Phase 3 Completed
NCT00459277 2012-01-25
Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Archimedes Development Ltd
Phase 3 Completed
NCT00236327 2011-05-17
Evaluation of the Efficacy and Safety of Fentanyl Delivered by Adhesive Skin Patch in Out-Patients With Chronic Cancer Pain
Janssen Cilag S.A.S.
Phase 4 Terminated
NCT00216658 2011-01-24
Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -
Janssen Pharmaceutical K.K.
Phase 2 Completed
NCT00589823 2010-01-22
Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Archimedes Development Ltd
Phase 3 Completed